Caramia G, Franceschini F, Cimarelli Z A, Ciucchi M S, Gagliardini R, Ruffini E
Division Pediatric, Salesi Hospital of Ancona, Italy.
Allerg Immunol (Paris). 1996 Nov;28(9):308-10.
A double blind study was made on a group of 35 children, 8 of whom were allergic to Grass and 27 allergic to Pteronyssinus and Farinae Dermatophagoides. We verified the efficacy and tolerability of a new immunotherapy called E.P.D. (Enzyme Potentiated Desensitization). This particular immunotherapy consists in an intradermal injection of a mix made up of an allergic solution at extremely low doses and an enzyme, beta-glucuronidase. The vaccine is administered once a year, two weeks before pollen peaks for children with seasonal allergies and two times a year, in February and November, for children with non-seasonal allergies (Dermatophagoides). The results, statistically analyzed on the basis of a symptoms score, showed good clinical efficacy in patients affected by both seasonal and non-seasonal allergies. Due to the clinical effectiveness, easy administration and excellent tolerability of the immunotherapy, E.P.D. is particularly suited for treating or reducing allergic symptoms in allergic children.
对一组35名儿童进行了双盲研究，其中8名对草过敏，27名对螨和粉螨过敏。我们验证了一种名为E.P.D.（酶增强脱敏疗法）的新型免疫疗法的疗效和耐受性。这种特殊的免疫疗法包括皮内注射一种由极低剂量的过敏溶液和一种酶（β-葡萄糖醛酸酶）组成的混合物。对于季节性过敏的儿童，疫苗在花粉高峰期前两周每年注射一次；对于非季节性过敏（螨过敏）的儿童，每年在2月和11月注射两次。根据症状评分进行统计分析的结果显示，该疗法对季节性和非季节性过敏患者均具有良好的临床疗效。由于该免疫疗法具有临床有效性、给药方便且耐受性良好的特点，E.P.D.特别适合用于治疗或减轻过敏儿童的过敏症状。
